These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1014 related items for PubMed ID: 32860288

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T, Zhang Z, Luo F, Zhao Y, Hou X, Liu T, Wang K, Zhao H, Huang Y, Zhang L.
    JAMA Netw Open; 2020 Oct 01; 3(10):e2015748. PubMed ID: 33074323
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
    Liu X, Xing H, Zhang H, Liu H, Chen J.
    Immunotherapy; 2021 Aug 01; 13(12):989-1000. PubMed ID: 34114477
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    Asao T, Watanabe S, Tanaka T, Morita S, Kobayashi K.
    BMC Cancer; 2022 Nov 04; 22(1):1135. PubMed ID: 36333680
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
    Yang Y, Ai X, Xu H, Yang G, Yang L, Hao X, Yang K, Mi Y, Wang G, Zhang S, Lei S, Wang Y.
    Thorac Cancer; 2022 Dec 04; 13(23):3295-3303. PubMed ID: 36218023
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    Qin B, Xin L, Liang C, Li L, Song Q, Long Y, Zhang X, Wang D, Shi W, Zhang J, Hu Y, Yang B, Xiong Q.
    BMC Cancer; 2024 Jan 17; 24(1):100. PubMed ID: 38233798
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T, Li W, Diwu D, Chen L, Chen X, Wang H.
    Front Immunol; 2023 Jan 17; 14():1197044. PubMed ID: 37435087
    [Abstract] [Full Text] [Related]

  • 36. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
    Xue L, Chen B, Lin J, Peng J.
    Ann Palliat Med; 2021 Jan 17; 10(1):828-835. PubMed ID: 33545805
    [Abstract] [Full Text] [Related]

  • 37. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
    Arriola E, González-Cao M, Domine M, De Castro J, Cobo M, Bernabé R, Navarro A, Sullivan I, Trigo JM, Mosquera J, Crama L, Isla D.
    Oncol Ther; 2022 Jun 17; 10(1):167-184. PubMed ID: 35032007
    [Abstract] [Full Text] [Related]

  • 38. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
    Peng J, Zhang L, Wang L, Feng H, Yao D, Meng R, Liu X, Li X, Liu N, Tan B, Huang Z, Li S, Meng X.
    Radiat Oncol; 2023 Jul 04; 18(1):111. PubMed ID: 37403111
    [Abstract] [Full Text] [Related]

  • 39. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM, Madhira BR, Ashraf S, Graziano S.
    Oncology; 2020 Jul 04; 98(11):749-754. PubMed ID: 32663833
    [Abstract] [Full Text] [Related]

  • 40. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
    Wang BC, Fu C, Lin GH.
    Front Immunol; 2023 Jul 04; 14():1185577. PubMed ID: 37215120
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.